

Samuel Yu-Shan Wang, Ph.D.

General Manager

Johnpro Biotech Inc. Taipei, Taiwan

&

Adjunct Assistant Professor

Inst. of Molecular Medicine and Bioengineering

National Chiao Tung University, Hsin-Chu, Taiwan

Educations:

2002/09-2008/07 Cancer Research Center, School of Veterinary Medicine, National Taiwan University, PhD program

1997/09-1999/07 Institute of Biotechnology in Medicine, National Yang-Ming University, the degree of Master of Science

1993/09-1997/06 Faculty of Biomedical Science and Environmental Biology, Kaohsiung Medical University, the degree of Bachelor of Science

Academic Appointment:

2017-present Institution of Molecular Medicine and Bioengineering, National Chiao Tung University, Adjunct Assistant Professor

2012-2014 Department of earth and Life Science, University of Taipei, Adjunct Assistant Professor

2009-2013 Department of Biotechnology and Animal Science, National Ilan University, Adjunct Assistant Professor

2009 First Department of Pathology, Sapporo Medical University, Visiting Scholars

2003-present Department of Radiation Therapy and Oncology, Shin Kong Wu Ho-Su Memorial Hospital, Scientific Researcher/ Consultant

Award:

Scholarship Winner, Keystone Symposia, Cytokine, Disease and Therapeutic Intervention, Santa Fe, New Mexico, USA, 2005

Research Award, College of Bioresources, National Taiwan University, Taipei, Taiwan, 2007

Brief introduction

Dr. Samuel Yu-Shan Wang is general manager of Johnpro Biotech Inc., and an adjunct

assistant professor at Inst. of Molecular Medicine and Bioengineering, National Chiao Tung University. He received his Ph.D. degree in cancer immunology from the National Taiwan University School of Veterinary Medicine in 2008. Dr. Wang joined the Department of Radiotherapy and Oncology, Shih Kong Memorial Hospital as a research fellow in 2008 and spent the next few years studying the interaction between immune system and tumor microenvironment.

Dr. Wang joined Johnpro Biotech Inc. in 2015 as co-founder to develop the anti-cancer agents that synergistic with tumor microenvironment and hyperthermia. Dr. Wang's efforts in this field have earned him numerous publications and patents and have led to the development of the tumor metabolic modulator agent and hyperthermia sensitizer agent as cancer therapeutic drugs. Dr. Wang continues to pursue his research interests in developing technologies and applications for combined cancer therapy in different fields, including cancer immunotherapy.